CA2391650C - Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl - Google Patents

Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Download PDF

Info

Publication number
CA2391650C
CA2391650C CA2391650A CA2391650A CA2391650C CA 2391650 C CA2391650 C CA 2391650C CA 2391650 A CA2391650 A CA 2391650A CA 2391650 A CA2391650 A CA 2391650A CA 2391650 C CA2391650 C CA 2391650C
Authority
CA
Canada
Prior art keywords
compound
accordance
formula
polymorph
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2391650A
Other languages
English (en)
French (fr)
Other versions
CA2391650A1 (en
Inventor
Sophie-Dorothee Clas
Chad Dalton
Louis S. Crocker
James A. Mccauley
Ian Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd, Merck Sharp and Dohme LLC filed Critical Merck Frosst Canada Ltd
Publication of CA2391650A1 publication Critical patent/CA2391650A1/en
Application granted granted Critical
Publication of CA2391650C publication Critical patent/CA2391650C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA2391650A 1999-11-29 2000-11-27 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Expired - Lifetime CA2391650C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29
US60/167,922 1999-11-29
PCT/US2000/032353 WO2001037833A1 (en) 1999-11-29 2000-11-27 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Publications (2)

Publication Number Publication Date
CA2391650A1 CA2391650A1 (en) 2001-05-31
CA2391650C true CA2391650C (en) 2011-01-25

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2391650A Expired - Lifetime CA2391650C (en) 1999-11-29 2000-11-27 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (https=)
EP (1) EP1248618B1 (https=)
JP (1) JP4425514B2 (https=)
AT (1) ATE320809T1 (https=)
AU (1) AU776544B2 (https=)
CA (1) CA2391650C (https=)
DE (1) DE60026877T2 (https=)
DK (1) DK1248618T3 (https=)
ES (1) ES2259295T3 (https=)
PT (1) PT1248618E (https=)
WO (1) WO2001037833A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
PL2479166T3 (pl) 2009-02-27 2014-11-28 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
EP2831045A2 (en) * 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
HU227627B1 (en) * 1998-04-24 2011-10-28 Merck Sharp & Dohme Process for synthesizing pyridine derivatives as cox-2 inhibitors and the intermediates
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
US6441002B1 (en) 2002-08-27
EP1248618A4 (en) 2003-05-14
JP4425514B2 (ja) 2010-03-03
AU776544B2 (en) 2004-09-16
US20030144327A1 (en) 2003-07-31
ATE320809T1 (de) 2006-04-15
US20020198238A1 (en) 2002-12-26
EP1248618A1 (en) 2002-10-16
CA2391650A1 (en) 2001-05-31
DE60026877T2 (de) 2006-11-23
AU1803101A (en) 2001-06-04
WO2001037833A1 (en) 2001-05-31
DK1248618T3 (da) 2006-07-10
JP2003514859A (ja) 2003-04-22
DE60026877D1 (de) 2006-05-11
EP1248618B1 (en) 2006-03-22
PT1248618E (pt) 2006-07-31
ES2259295T3 (es) 2006-10-01

Similar Documents

Publication Publication Date Title
CA2391650C (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
JP5714824B2 (ja) １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相
CA2410234C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
EP2350009B1 (en) Sulfonate salts of flupirtine
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
US6858631B1 (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
AU2001292907A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
TWI687413B (zh) 製備吡蟲啉（ｉｍｉｄａｃｌｏｐｒｉｄ）多晶型的方法
KR20230165774A (ko) 4h-피란-4-온 구조의 cyp11a1 억제제의 고체 형태
JP2023531078A (ja) 化合物の結晶形態
US6800647B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
JP6985137B2 (ja) スルホンアミド化合物の結晶形
WO2010097583A1 (en) Esomeprazole potassium polymorph and its preparation
EP1742628A1 (en) Alternative forms of the phosphodiesterase-4 inhibitor n-cyclopropyl-1-{3-¬(1-oxidopryidin-3-yl)ethynyl|phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
MXPA06008491A (en) Crystal forms of e-2-methoxy -n-(3-{4-[3-methyl -4-(6-methyl- pyridin-3 -yloxy)-phenylamino]-quinazolin-6-yl} -allyl)- acetamide

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201127